We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death ...

Receipt of a cardiac-resynchronization therapy-defibrillator (CRT-D) offers long term benefit for patients with heart failure, reduced ejection fraction, and a widened QRS complex, according to a ...

Shanghai, China - The first patient implants of the Boston Scientific Corporation COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully performed in China’s Zhejiang ...

Reduced cardiac efficiency caused by suboptimal synchronization of the heart's normal contraction might contribute to the development of or exacerbate heart failure. Conceptually and in practice ...

Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...

Medtronic CRT-D Devices Demonstrate Survival Benefits for Mildly Symptomatic Heart Failure Patients in Two Pivotal Clinical Trials MINNEAPOLIS – Medtronic, Inc. today announced that the U.S. Food and ...

LOS ANGELES (March 8, 2002) – Patients who suffer from advanced congestive heart failure and heart rhythm abnormalities may qualify to participate in one of two research trials now underway at ...

Cardiac resynchronization therapy (CRT), with or without a defibrillator, has been shown to improve symptoms, quality of life, and prognosis in patients with moderate-to-severe heart failure (HF) ...

Pacemakers and other implantable devices that restore normal heart rhythms have saved millions of lives. In some patients, a pacemaker or implantable cardioverter defibrillator modified for "cardiac ...

The European Society of Cardiology (ESC) has released updated guidelines for cardiac pacing and cardiac resynchronization therapy (CRT), which emphasize patient-centered care and shared ...

DUBLIN, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE (Conformité Européenne) Mark for its Cobalt™ and Crome™ portfolio of implantable ...

BIOTRONIK today announced the launch of the new Acticor Sky and Rivacor Sky device family featuring the world's first CE-approved left bundle branch area pacing (LBBAP) high-voltage device. These next ...